RBMY2CP

Q-omics provides the consensus-scored RBMY2CP profile across patient tissues and cancer cell-line models. RBMY2CP expression is associated with patient survival in 2 of 34 cancer types, with the highest sampling consensus in OV. Additionally, RBMY2CP RNA expression shows 39 significant mutation-linked associations, with the highest sampling consensus in PRAD. Together, these results highlight OV, and PRAD as cancer lineages where RBMY2CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.

Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.

Survival associations

This table summarizes RBMY2CP survival associations across molecular data types. RBMY2CP RNA expression shows survival associations in the most cancer types (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.

RBMY2CP data type	Survival analysis	Lineage consensus	Lineage of highest sampling consensus
RNA	Kaplan–Meier	2	OV (108)	view →

This table ranks reproducible RBMY2CP RNA expression–survival associations across cancer types. High RBMY2CP expression shows unfavorable associations in OV and ESCA. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for RBMY2CP RNA expression.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	II,III,IV	0.021	0.844	<.001	108	view →
ESCA	DFS	Tertile	All	0.147	0.536	.006	27	view →

Pink = unfavorable, green = favorable. all 2 lineages →

RBMY2CP-OV (OS)

Explore this curve interactively →